Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Hewlett Packard Enterprise Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.76 (market cap $5.07B), while Hewlett Packard Enterprise Co trades at $56.8 (market cap $72.01B). The key difference: Hewlett Packard Enterprise Co is far larger — about 14.2× ACADIA Pharmaceuticals Inc.'s market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HPE | |
|---|---|---|
Market Cap | $5.07B | $72.01B |
Sector | Health | Technology |
52-Week High | $29.41 | $56.14 |
52-Week Low | $20.06 | $20.01 |
Enterprise Value | $4.19B | $87.96B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
HPE stock trades at $56.32, up 3.02% with strong momentum following recent analyst upgrades. The company shows robust earnings beats in recent quarters with Q1 2026 EPS of $0.79 beating expectations of $0.535. Technical indicators suggest bullish momentum while fundamentals show revenue growth to $34.3B in 2025, though net income declined significantly to $57M. Recent Morgan Stanley upgrade highlights AI infrastructure strength.
Outlook remains positive with AI-driven growth potential, though elevated P/E ratio of 50.82 warrants caution. Key risks include competitive pressures in server markets and execution challenges. Analyst consensus price target of $69.81 offers 24% upside potential from current levels, supported by institutional buying interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
